Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
crofelemer
Intellectual property
Napo has received composition of matter patents for crofelemer in the United States, Japan, Canada, Australia, Korea, Mexico, United Kingdom and the Netherlands.
The company has filed a patent for enteric-coated formulations of crofelemer worldwide, and has received such patent approval in the United States, New Zealand, Australia, Korea, Taiwan, Japan, India and Europe and two enteric-coated patents issued in the United States. Several other patents are currently being prosecuted in the United States and around the world.